Dianthus Therapeutics, Inc./$DNTH
Dianthus Therapeutics shares fall as investors reassess claseprubart’s prospects after Sanofi scrapped a Phase 3 trial of a rival C1s inhibitor and reports raised broader safety and regulatory concerns for complement blockers.
17 hours agoLightyear AI
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Dianthus Therapeutics, Inc.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
- Ticker
- $DNTH
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 92
- Headquarters
- New York, United States
- Website
- dianthustx.com
DNTH Metrics
BasicAdvanced
$4B
-
-$4.11
0.08
-
Price and volume
Market cap
$4B
Beta
0.08
52-week high
$117.88
52-week low
$32.22
Average daily volume
928K
Financial strength
Current ratio
26.1
Quick ratio
25.791
Long term debt to equity
0.001
Total debt to equity
0.001
Profitability
EBITDA (TTM)
-217.721
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-10,096.95%
Operating margin (TTM)
-11,441.39%
Revenue per employee (TTM)
$20,000
Management effectiveness
Return on assets (TTM)
-17.69%
Return on equity (TTM)
-26.07%
Valuation
Price to revenue (TTM)
1,769.731
Price to book
3.37
Price to tangible book (TTM)
3.37
Price to free cash flow (TTM)
-21.64
Free cash flow yield (TTM)
-4.62%
Free cash flow per share (TTM)
-3.331
Growth
Revenue change (TTM)
-60.77%
Earnings per share change (TTM)
26.59%
3-year revenue growth (CAGR)
-20.53%
3-year earnings per share growth (CAGR)
-22.98%
What the Analysts think about DNTH
Analyst ratings (Buy, Hold, Sell) for Dianthus Therapeutics, Inc. stock.
Analyst projections of the future price of Dianthus Therapeutics, Inc. stock.
Bulls say / Bears say
In CIDP, 75% of the first 40 CAPTIVATE Part A completers responded, above the 50% target, and the company reported no related serious infections or safety-related discontinuations. This provides encouraging early evidence for claseprubart, although the placebo-controlled Part B is still to come. (GlobeNewswire)
Results from the Phase 2 MaGic trial showed statistically significant improvements versus placebo across five gMG measures at Week 13 for the 300mg dose. Dianthus has moved claseprubart into a Phase 3 registrational trial, giving the programme a second major indication to pursue. (StockTitan, GlobeNewswire)
Dianthus had about $1.2bn in cash, cash equivalents and investments at the end of June and expects this to fund operations into 2030. That gives it substantial capacity to run several trials and reach important data milestones without near-term financing pressure. (GlobeNewswire)
Sanofi halted a late-stage CIDP trial of riliprubart, another C1s inhibitor, after efficacy concerns. That result raises a relevant warning for Dianthus: claseprubart’s shared target does not guarantee success in the same disease. (Seeking Alpha)
The 75% CIDP response rate came from the first 40 participants in Part A, before the placebo-controlled Part B confirms whether treatment prevents relapse. The gMG Phase 3 trial is also not expected to report top-line results until the second half of 2028, leaving key clinical and timing risks unresolved. (GlobeNewswire)
Dianthus reported a $50.2m net loss in Q2, while research and development costs rose to $48.7m from $26.3m a year earlier. Continued trial expansion is costly, and further equity issuance could dilute shareholders. (SEC, Simply Wall St)
Data summarised monthly by Lightyear AI. Last updated on 16 Oct 2026.
DNTH Financial Performance
Revenues and expenses
DNTH Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing DNTH
AllUSDEURGBP
Fund name | Fund size | $DNTH weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.41% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.41% |
iShares Healthcare Innovation£DRDR | £1B | 0.41% |
iShares Ageing Population$AGED | $953M | 0.36% |
iShares Ageing Population€AGED | €822M | 0.36% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.